Date Closed

March 4, 2013

Lead Office

Québec City

Value

7.00 Million CAD

On March 4, 2013, TSO3 Inc. ("TSO3" or the "Company") announced that it had successfully completed its previously announced public offering of 7 million common shares (the "Common Shares"). The offering was completed on a bought deal basis through a syndicate of underwriters co-led by Desjardins Securities Inc. and Canaccord Genuity Corp. and including Byron Capital Markets Ltd. and Laurentian Bank Securities Inc., at a price of C$1.00 per Common Share for aggregate gross proceeds to TSO3 of C$7 million (the "Offering").

The Common Shares were offered through a short-form prospectus filed in all provinces of Canada. The Common Shares being issued in the offering have been approved for listing on the Toronto Stock Exchange. Following the issuance of the shares, there are 72,888,182 Common Shares of TSO3 issued and outstanding.

Net proceeds from the Offering will be used to accelerate new product development, strengthen the Company's financial position enabling the Company to continue to actively pursues US regulatory clearance for the STERIZONE® 125L+ Sterilizer, and negotiate an appropriate channel partner agreement.

TSO3, headquartered in Québec City, Québec, specializes in the research and development of innovating, high-performance medical instrument sterilization technology with high commercial potential.

McCarthy Tétrault LLP represented Desjardins Securities, the underwriter, with a team led by Philippe Leclerc.